Koelis, SAS

Koelis is a medical technology company focused on innovative solutions for prostate cancer detection and management. Its flagship product, KOELIS Trinity®, combines advanced imaging techniques for enhanced precision in biopsies. Founded in 2006 in France, Koelis specializes in medical imaging technologies for prostate cancer. The company operates without known subsidiaries and has not undergone significant changes in its business strategy.

The founders, Antoine Leroy and Patrick Henri, bring extensive expertise in medical technology. In April 2022, Koelis secured EUR 10 million in a GROWTH funding round led by InnovaHealth Partners, marking a total amount raised of EUR 10 million through 2 deals to date. KOELIS® specializes in advanced medical technologies for prostate cancer detection and management, with its flagship product being the KOELIS Trinity®, a fully integrated mobile fusion imaging platform. This innovative platform combines MRI and ultrasound imaging to enhance the precision of prostate biopsies, enabling physicians to target both explored and unexplored areas of the prostate with millimetric accuracy.

The technology includes a unique 3D prostate mapping tool and the OBT Fusion® technology, which allows for real-time tracking of the prostate and needle guidance during procedures. KOELIS® primarily serves healthcare professionals and institutions in the oncology field, including urologists and hospitals, across various international markets, including Europe, the United States, and parts of Asia. These advanced tools are designed to optimize clinical decision-making processes and facilitate personalized care for patients diagnosed with prostate cancer. In 2022, Koelis reported a revenue of EUR 10,374,871.

40, with an EBITDA of EUR 1,034,084. 40. The company generates revenue through direct sales of its proprietary medical imaging systems, including the KOELIS Trinity® and its associated technologies, primarily targeting healthcare institutions. Following the investment in April 2022, Koelis plans to use the EUR 10 million funding to expand its clinical and technology services focused on prostate cancer diagnosis and treatment.

The company is expected to introduce new products designed to enhance its imaging technology and strengthen partnerships in existing markets while exploring opportunities in new regions. Specific geographic expansions and product timelines have not been disclosed.